LTP

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

Retrieved on: 
Donnerstag, Juni 6, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Presenteeism, Physical, JDA, Patient, Employment, Subgroup analysis, Geography, KALV, HAE, First, Asthma, Hereditary angioedema, Quality of life, Mental, LTP, Social isolation, EAC, Annual general meeting, Attack, Conference, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024, as well as the Japanese subgroup from KONFIDENT at the 123rd Annual Meeting of the Japanese Dermatological Association (JDA) 2024.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented the US subgroup analysis from the sebetralstat phase 3 KONFIDENT trial and real-world claims and patient survey data at the Eastern Allergy Conference (EAC) 2024, as well as the Japanese subgroup from KONFIDENT at the 123rd Annual Meeting of the Japanese Dermatological Association (JDA) 2024.
  • KONFIDENT is the first pivotal phase 3 trial to include Japanese sites in an HAE development program.
  • (Poster presentation)
    Real-world Impact of Treated Hereditary Angioedema Attacks on Patients’ Employment and Work Productivity: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States.
  • In parallel, claims data also highlight that on-demand prescription volumes have remained stable despite the introduction of subcutaneous and oral long-term prophylaxis options.

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Retrieved on: 
Sonntag, Juni 2, 2024
Perception, Myalgia, LTP, Patient, Berotralstat, Internal medicine, Acne, Cohort (statistics), Cancer, Dermatology, Hereditary angioedema, BioCryst Pharmaceuticals, Human, Liver, Translational medicine, Menstruation, Liver cancer, Virilization, Risk, HAE, Diagnosis, Androgen, Fraunhofer Society, Physician, Congress, EAACI, Tranexamic acid, Pharmaceutical industry

The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.

Key Points: 
  • The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.
  • “The diagnosis of HAE patients with normal C1-inhibitor is complicated and often delayed by the lack of an easily measurable biochemical marker.
  • One patient experienced gastrointestinal symptoms upon initiation, which became milder after the first two weeks and did not lead to treatment discontinuation.
  • Additional new results presented at EAACI demonstrate the adverse health outcomes associated with attenuated androgen use as a prophylactic treatment for HAE.

Gate Neurosciences to Share New Data and Research Insights on its Synaptic Function Molecules with Multiple Posters at 2024 ASCP Annual Meeting

Retrieved on: 
Mittwoch, Mai 15, 2024
Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, CSF, NMDAR, Poster, NMDA, Biological Psychiatry (journal), Society, Psychiatry, LTP, Annual general meeting, CNS, Biomarker, Quantitative electroencephalography, Medicine, ASCP, Gate, Neuroscience, Pharmaceutical industry

The company will present new preclinical and clinical data supporting its NMDAR PAM portfolio and will share novel insights from internal research on the biological mechanisms of neuroplasticity and synaptic function.

Key Points: 
  • The company will present new preclinical and clinical data supporting its NMDAR PAM portfolio and will share novel insights from internal research on the biological mechanisms of neuroplasticity and synaptic function.
  • Specifically, Gate Neurosciences will highlight its cutting-edge research on how a single dose of neuroplasticity-enhancing drugs can trigger both rapid-onset (i.e.
  • Gate Neurosciences 3rd Annual R&D Day at ASCP 2024:
    “Over the past few years, the Gate team has made considerable progress in understanding mechanisms that rapidly and durably enhance synaptic function for treating CNS diseases.
  • Key takeaways include:
    Full abstracts will be published by ASCP following the conclusion of the 2024 Annual Meeting.

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

Retrieved on: 
Donnerstag, Mai 9, 2024
University, International Society, Poster, BioCryst Pharmaceuticals, LTP, MD, History, Documentation, Hereditary angioedema, Patient, Medicine, HRU, HAE, Pharmacoeconomics, Disease, Pharmaceutical industry

“The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.

Key Points: 
  • “The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.
  • This outcome provides a compelling argument that ORLADEYO, which is known to be effective in reducing HAE morbidity, is also a cost-effective strategy for patient management.
  • The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States.
  • We look forward to reporting additional real-world evidence that highlights the benefits associated with long-term prophylaxis with ORLADEYO,” said Dr. William Sheridan, chief development officer and interim chief medical officer of BioCryst.

South Africa Tobacco Industry Report 2024: The Vape Market is Growing Strongly, but Excise Duties Introduced in 2023 and Proposed Regulation is Causing Concern about Profitability - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 7, 2024
Tobacco, Retail, Competition, Health, LTP, Tobacco industry, Japan Tobacco International, Philip Morris, American Tobacco Company, Smoker, CBD, Environment, Legislation, Gold leaf, British American Tobacco, Growth

South Africa's tobacco industry is facing enormous challenges from an illicit cigarette market that entrenched itself during the five-month tobacco sales ban in 2020.

Key Points: 
  • South Africa's tobacco industry is facing enormous challenges from an illicit cigarette market that entrenched itself during the five-month tobacco sales ban in 2020.
  • Tobacco products and vape companies are concerned that legislation bringing e-cigarettes into the regulatory and tax net will destroy the industry.
  • The vape market is growing strongly, but excise duties introduced in 2023 and proposed regulation is causing concern about profitability.
  • This report on the tobacco and tobacco products industry includes information on tobacco farming and processing, cigarette manufacturing and tobacco, e-cigarettes, and tobacco heating products.

Gate.io Successfully Concludes the Gate.io VC & Web3 Ecosystem Party at TOKEN2049

Retrieved on: 
Mittwoch, April 24, 2024
Cloud, User, VCS, Cryptocurrency, Internet, Cloud computing, LTP, Person

Dubai, United Arab Emirates--(Newsfile Corp. - April 24, 2024) - Gate.io, a top crypto exchange and Web3 innovator, and Huawei Cloud, a leading cloud computing provider delivering cutting-edge Web3 infrastructure, successfully co-hosted the 'Token2049 Gate.io Exclusive Night VC & Web3 Ecosystem Party' side event on April 19 at TOKEN2049 Dubai.

Key Points: 
  • Dubai, United Arab Emirates--(Newsfile Corp. - April 24, 2024) - Gate.io, a top crypto exchange and Web3 innovator, and Huawei Cloud, a leading cloud computing provider delivering cutting-edge Web3 infrastructure, successfully co-hosted the 'Token2049 Gate.io Exclusive Night VC & Web3 Ecosystem Party' side event on April 19 at TOKEN2049 Dubai.
  • Hundreds of guests attended the event, which featured speakers from various projects, VCs, blockchain ecosystems, and institutional firms.
  • The event commenced with Dr. Lin Han's opening speech, addressing the challenges of integrating blockchain technology into daily activities and emphasizing the importance of infrastructure solutions.
  • The event also included two engaging panel discussions with speakers from Huawei Cloud, M55 Capital, and many other reputable companies.

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Retrieved on: 
Montag, März 18, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Disease, Patient, LTP, Hereditary angioedema, HAE, Quality of life, Anxiety, University, KALV, Return, Treatment, Quality, Asthma, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.
  • “These data show once again that people living with HAE still face challenges in following established guidelines for treating their attacks,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • “Even short treatment delays can lead to worse clinical outcomes, and despite efficacious on-demand treatments, the fact that they need to be injected results in barriers which lead to significant underuse and resultant overuse of long-term prophylaxis.
  • (Poster Presentation)
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users

EQS-News: Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
Mittwoch, März 13, 2024
Neurotoxicity, Learning, Myenteric plexus, Conference, Penile spines, Therapy, Memory, LTP, DSM-IV codes, Poster, Science, IND, Dendrite, Pharmaceutical industry

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
Freitag, März 8, 2024
Neurotoxicity, Learning, Myenteric plexus, Conference, Penile spines, Therapy, Memory, LTP, DSM-IV codes, Poster, Science, IND, Dendrite, Pharmaceutical industry

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Mittwoch, Februar 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.